NLM Digital Collections

Search

Start Over Collections Health Policy and Services Research ✖Remove constraint Collections: Health Policy and Services Research Subjects Drug Costs ✖Remove constraint Subjects: Drug Costs

1. State Pharmacy Assistance Programs vs. Medicare prescription drug plans: how do they contain rising costs?

Publication:
[Washington, D.C.] : AcademyHealth, [2005]
Subject(s):
Cost Control
Medicare -- economics
State Health Plans -- economics
Cost Sharing
Drug Costs
Drug Utilization Review
Drugs, Generic
Fees, Pharmaceutical
Formularies as Topic
Insurance Coverage -- legislation & jurisprudence
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- legislation & jurisprudence
Medicare -- legislation & jurisprudence
Humans
United States

3. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

4. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

5. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017
Subject(s):
Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
Abatacept -- economics
Certolizumab Pegol -- economics
Cost Savings
Injections -- economics
Self Care -- economics
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system

6. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Medicaid -- economics
Pharmaceutical Preparations -- classification
Pharmaceutical Preparations -- economics
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

7. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

10. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

Author(s):
Doshi, Jalpa A., author
Li, Pengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Kumar, Rishab, author
Weiss, Brendan M., author
Huntington, Scott F., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
Subject(s):
Cost Sharing
Drug Costs
Medicare Part D -- economics
Financing, Personal
Health Services Accessibility
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Protein Kinase Inhibitors -- economics
Protein Kinase Inhibitors -- therapeutic use
Protein-Tyrosine Kinases -- antagonists & inhibitors
Humans
United States